Drug Profile


Alternative Names: JNJ-27018966; Mu Delta; TRUBERZI; VIBERZI

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen Pharmaceutica
  • Developer Allergan
  • Class Amides; Benzoic acids; Imidazoles; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Opioid delta receptor antagonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Irritable bowel syndrome

Most Recent Events

  • 27 Jul 2017 The National Institute of Health and Care Excellence recommends availability of eluxadoline on the National Health Service for adult patients with Irritable bowel syndrome with diarrhoea
  • 26 Jul 2017 NICE expects to publish the final guidance for eluxadoline in Irritable bowel syndrome with diarrhoea at the end of August 2017
  • 10 Jul 2017 Efficacy data from a prospective pooled subgroup analysis from two phase III trials in Irritable bowel syndrome released by Allergan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top